Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SYSCID

Financiado

Cerrado

A Systems medicine approach to chronic inflammatory disease

"The SYSCID consortium aims to develop a systems medicine approach for disease prediction in CID. We will focus on three major CID indications with distinct characteristics, yet a large overlap of their molecular risk map: inflamm... ver más

30/09/2022

CAU

16M€

Presupuesto del proyecto: 16M€

Líder del proyecto

CHRISTIANALBRECHTSUNIVERSITAET ZU KIEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 18 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-09-30

SC1-PM-01-2016: Multi omics for personalised therap...

I+D

Cerrada hace 8 años

0% 90% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

18 Participantes

CAU

2.85M€ | Lider

ENERGIAS FOTOVOLTAICAS DE NA...

BIOMEDICAL RESEARCH FOUNDATI...

604.23K€ | Participante

RHEINISCHE FRIEDRICHWILHELMS...

1.26M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IMMEDIATE Imminent Disease Prediction and Prevention at the Environmen... 6M€ Cerrado

COSMIC COmbatting disorders of adaptive immunity with Systems MedIC... 4M€ Cerrado

miGut-Health Personalised blueprint intestinal health 7M€ Cerrado

ExpoBiome Deciphering the impact of exposures from the gut microbiome... 2M€ Cerrado

ImmunAID Immunome project consortium for AutoInflammatory Disorders 16M€ Cerrado

IMCIS Individualised medicine in chronic inflammatory skin disease... 1M€ Cerrado

Duración del proyecto: 69 meses Fecha Inicio: 2016-12-01
Fecha Fin: 2022-09-30

Líder del proyecto

CHRISTIANALBRECHTSUNIVERSITAET ZU KIEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 16M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "The SYSCID consortium aims to develop a systems medicine approach for disease prediction in CID. We will focus on three major CID indications with distinct characteristics, yet a large overlap of their molecular risk map: inflammatory bowel disease, systemic lupus erythematodes and rheumatoid arthritis. We have joined 15 partners from major cohorts and initiatives in Europe (e.g.IHEC, ICGC, TwinsUK and Meta-HIT) to investigate human data sets on three major levels of resolution: whole blood signatures, signatures from purified immune cell types (with a focus on CD14 and CD4/CD8) and selected single cell level analyses. Principle data layers will comprise SNP variome, methylome, transcriptome and gut microbiome. SYSCID employs a dedicated data management infrastructure, strong algorithmic development groups (including an SME for exploitation of innovative software tools for data deconvolution) and will validate results in independent retrospective and prospective clinical cohorts. Using this setup we will focus on three fundamental aims : (i) the identification of shared and unique ""core disease signatures which are associated with the disease state and independent of temporal variation, (ii) the generation of ""predictive models of disease outcome""- builds on previous work that pathways/biomarkers for disease outcome are distinct from initial disease risk and may be shared across diseases to guide therapy decisions on an individual patient basis, (iii) ""reprogramming disease""- will identify and target temporally stable epigenetic alterations in macrophages and lymphocytes in epigenome editing approaches as biological validation and potential novel therapeutic tool . Thus, SYSCID will foster the development of solid biomarkers and models as stratification in future long-term systems medicine clinical trials but also investigate new causative therapies by editing the epigenome code in specific immune cells, e.g. to alleviate macrophage polarization defects."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores